+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Hypothalamic-pituitary-adrenocortical axis changes in the rat after long-term treatment with the reversible monoamine oxidase-A inhibitor moclobemide



Hypothalamic-pituitary-adrenocortical axis changes in the rat after long-term treatment with the reversible monoamine oxidase-A inhibitor moclobemide



Neuroendocrinology 60(5): 509-519



The effects of the reversible monoamine oxidaseA (MAOA) inhibitor moclobemide on the rat hypothalamic-pituitary-adrenocortical (HPA) axis were studied. The time-course experiments showed that moclobemide, given via the drinking water (4.5 mg/kg/day), produces significant decreases (p < 0.05) in adrenal weight after 5 (-23%) and 7 weeks (-16%) of treatment. It was found that long-term moclobemide treatment had neuroanatomically distinct effects on corticosteroid receptor expression. Hippocampal mineralocorticoid receptor (MR) levels were upregulated at 2 (+65%), 5 (+76%) and 7 (+19%) weeks of treatment. Glucocorticoid receptor (GR) levels in this limbic brain structure were slightly up-regulated by 10% at 5 weeks, and indistinguishable from controls after 2 and 7 weeks of treatment. After 5 weeks of treatment, MR levels were unchanged in the hypothalamus, and increased by 44, 24 and 28% in the neocortex, amygdala and anterior pituitary, respectively. GR concentrations were elevated by 24 and 14% in the hypothalamus and anterior pituitary, respectively, whereas neocortical and amygdaloid receptor levels were not altered. After 5 weeks of moclobemide treatment, marked decreases in [125I]Tyr0-ovine corticotropin-releasing hormone ([125I])-oCRH binding capacity and proopiomelanocortin (POMC) mRNA content were observed in the anterior pituitary. Regarding the functional implications of long-term anti-depressant treatment, moclobemide treatment (5 weeks, 4.5 mg/kg/day) significantly attenuated stress (30-min novel environment)-induced plasma ACTH (-35%) and corticosterone (-29%) levels; no changes were observed in basal plasma ACTH and corticosterone levels. In conclusion, this study shows that moclobemide has a concerted influence on multiple elements of the HPA axis manifesting functionally as a reduced neuroendocrine responsiveness to stress. In previous experiments, it was found that the structurally and pharmacologically distinct antidepressant amitriptyline after long-term administration also attenuated HPA axis activity. We postulate that an adjustement of HPA axis activity may be regarded as a common denominator for clinically efficacious antidepressant drugs.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 008797989

Download citation: RISBibTeXText

PMID: 7845541

DOI: 10.1159/000126788


Related references

Chronic treatment with the monoamine oxidase inhibitor phenelzine increases hypothalamic-pituitary-adrenocortical activity in male C57BL/6 mice: relevance to atypical depression. Endocrinology 146(3): 1338-1347, 2005

Long-term antidepressant drug treatment attenuates hypothalamic-pituitary-adrenocortical axis activity in the rat. Pharmacopsychiatry 28(5): 205, 1995

Successful treatment of tardive akathisia with moclobemide, a reversible and selective monoamine-oxidase-A inhibitor. A case study. Pharmacopsychiatry 24(6): 229-231, 1991

Moclobemide: a reversible inhibitor of monoamine oxidase type A. British Journal of Hospital Medicine 49(7): 497-499, 1993

Long-term voluntary exercise and the mouse hypothalamic-pituitary-adrenocortical axis: impact of concurrent treatment with the antidepressant drug tianeptine. Journal of Neuroendocrinology 18(12): 915-925, 2006

Clinical pharmacology of moclobemide, a new reversible monoamine oxidase inhibitor. Journal of Psychopharmacology 5(1): 82-91, 1991

Monoamine oxidase-A: Pharmacodynamics in humans of moclobemide, a reversible and selective inhibitor. British Journal of Clinical Pharmacology 37(5): 433-439, 1994

The effect of moclobemide, reversible inhibitor of Monoamine oxidase-A, on the alcoholized rat brain. Scandinavian Journal of Laboratory Animal Science 29(4): 217-225, 2002

Tyramine pressor response with moclobemide a reversible monoamine oxidase inhibitor. Psychiatry Research 22(3): 213-220, 1987

Interaction of moclobemide, a new reversible monoamine oxidase inhibitor with oral tyramine. Journal of Neural Transmission. Supplementum 26: 97, 1988

Moclobemide a new reversible monoamine oxidase inhibitor and tyramine interaction studies. Current Therapeutic Research 43(5): 903-917, 1988

Tolerability of moclobemide, a new reversible inhibitor of monoamine oxidase-A, compared with other antidepressants and placebo. Acta Psychiatrica Scandinavica. Supplementum 360: 24-28, 1990

Modification of the cardiovascular effects of ephedrine by the reversible monoamine oxidase A-inhibitor moclobemide. Journal of Cardiovascular Pharmacology 28(6): 856-861, 1996

Tyramine pressor effect in man: studies with moclobemide, a novel, reversible monoamine oxidase inhibitor. Journal of Neural Transmission. Supplementum 26: 57-71, 1988

Effect of the reversible monoamine oxidase a inhibitor moclobemide on sleep of depressed patients. European Journal of Pharmacology 183(4): 1386-1387, 1990